Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7466.092 | 0.9824 | 0.9615 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7466.092 | 1.0182 | 1.0397 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7466.092 | 0.9870 | 0.9717 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7466.092 | 0.9027 | 0.7884 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7466.092 | 0.0417 | -0.9378 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7466.092 | 0.0079 | -0.9899 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7467.091 | 0.9758 | 0.9627 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7467.091 | 0.9570 | 0.9334 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7467.091 | 1.0106 | 1.0162 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7467.091 | 0.9786 | 0.9670 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7467.091 | 0.9770 | 0.9645 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7467.091 | 0.9460 | 0.9163 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7467.091 | 0.8085 | 0.6982 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7467.091 | 0.0206 | -0.8990 | 1.2996 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7467.091 | 0.0031 | -0.9764 | 1.2996 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7468.091 | 0.9789 | 0.9715 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7468.091 | 0.9743 | 0.9653 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7468.091 | 0.9682 | 0.9570 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7468.091 | 0.9956 | 0.9941 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7468.091 | 1.0049 | 1.0066 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7468.091 | 0.9235 | 0.8957 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7468.091 | 0.8192 | 0.7487 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7468.091 | 0.0098 | -0.9114 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7468.091 | 0.0037 | -0.9542 | 1.4852 | |
| HCC38 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7469.09 | 1.0555 | 1.0552 | 1.9867 |